MEDI vs XLV

Key Takeaways

• MEDI is an actively managed, concentrated health care fund with roughly 40–45 holdings and a 0.80% expense ratio, while XLV is a passively managed, broadly diversified fund with about 63 holdings and a 0.08% expense ratio.
• MEDI tilts toward high-conviction growth and mid-cap biopharmaceutical names, whereas XLV tracks large-cap S&P 500 health care companies across pharmaceuticals, biotech, providers, and medical technology.
• Cost and diversification are the defining contrasts: XLV offers deep liquidity, lower volatility, and a meaningful dividend yield, while MEDI carries higher concentration and turnover risk in exchange for potential upside.
• XLV has far larger scale and tighter bid-ask spreads, whereas MEDI remains a smaller, less liquid fund with assets under management (AUM) in the tens of millions of dollars.
• Tickeron AI Verdict: XLV — the AI favors the lower-cost, better-diversified, and more liquid fund for most health care allocations.

Introduction

Health care remains one of the most strategically important sectors for portfolio construction, blending defensive cash flows with long-horizon innovation in pharmaceuticals, biotechnology, and medical devices. These two funds offer sharply different ways to access that theme. MEDI, the Harbor Health Care ETF, is an actively managed, concentrated portfolio seeking long-term capital growth. XLV, the Health Care Select Sector SPDR Fund, is a low-cost, passive vehicle tracking the S&P 500 health care universe. While both are 100% health care, they do not compete directly on strategy: one pursues high-conviction stock selection, the other broad, rules-based sector exposure. Comparing them highlights the trade-off between active risk-taking and structural efficiency.

Harbor Health Care ETF (MEDI) Overview

Launched in November 2022 and subadvised by Westfield Capital Management, MEDI is an actively managed, non-diversified fund that typically holds a narrow portfolio of roughly 30 to 50 global health care stocks. The fund is benchmarked to a health care growth index but does not replicate it; portfolio managers select securities based on valuation, financial strength, competitive positioning, and market opportunity. Its expense ratio is 0.80%, reflecting the cost of active management and relatively high portfolio turnover.

Concentration is MEDI's defining feature. Its two largest positions — LLY (Eli Lilly) and ASND (Ascendis Pharma) — have recently accounted for more than a third of assets, with other top holdings including GILD (Gilead Sciences), LEGN (Legend Biotech), RYTM (Rhythm Pharmaceuticals), and ABBV (AbbVie). The fund skews toward growth-oriented biotechnology and specialty pharmaceutical companies, with a meaningful mid-cap component and some non-U.S. exposure. Its smaller AUM and thinner trading volume can translate into wider spreads and higher total cost of ownership.

Health Care Select Sector SPDR Fund (XLV) Overview

Incepted in December 1998, XLV is one of the oldest and largest health care ETFs, managed passively by State Street Global Advisors. It seeks to track the Health Care Select Sector Index, which includes health care companies drawn from the S&P 500, using full replication. With roughly 60–70 holdings and an expense ratio of just 0.08%, it offers broad, low-cost exposure across pharmaceuticals, biotechnology, health care providers and services, equipment and supplies, and life sciences tools.

Top holdings include LLY (Eli Lilly), JNJ (Johnson & Johnson), ABBV (AbbVie), MRK (Merck), UNH (UnitedHealth Group), TMO (Thermo Fisher Scientific), and AMGN (Amgen). The portfolio is almost entirely large-cap and U.S.-listed, carries a dividend yield of roughly 1.6%, and exhibits a market beta well below 1.0 — characteristics that make it a relatively defensive, liquid vehicle with billions of dollars in AUM and tight bid-ask spreads.

Industry and Thematic Backdrop

Both funds operate within a health care sector shaped by several durable catalysts. Demand for GLP-1 weight-loss and diabetes therapies has reshaped pharmaceutical leadership, while innovation in cell and gene therapies, antibody-drug conjugates, and precision medicine continues to drive biotechnology momentum. At the same time, the sector faces regulatory scrutiny, drug-pricing policy debates, patent expirations, and election-driven headline risk around Medicare and reimbursement.

Macro conditions also matter. Health care is often treated as a defensive allocation during economic uncertainty, but rate-sensitive growth names can lag when bond yields rise. In recent market cycles, large-cap diversified health care has shown resilience, while smaller, pre-revenue biotech names have experienced sharper volatility. This divergence is central to how MEDI and XLV behave.

Performance and Positioning Comparison

In recent weeks and months, the two funds have reflected their structural differences. XLV, anchored by diversified large-cap leaders, has generally tracked broader health care stability with lower volatility and a modest income contribution. Its performance is driven by earnings cycles at mega-cap pharmaceuticals, managed-care providers, and medical device makers.

MEDI, by contrast, is more sensitive to idiosyncratic, stock-specific outcomes and biotechnology sentiment. Its heavy weighting in LLY and ASND means a single clinical or earnings event can move the entire fund materially. This concentration can amplify upside during risk-on biotechnology rallies but also magnifies drawdowns during rotations toward safety. In relative positioning terms, XLV offers consistency and breadth, while MEDI offers higher active risk and return dispersion.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of securities with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending names, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to refine your health care ETF comparison and identify relative positioning signals that match your strategy.

Tickeron AI Verdict

Based on observable structural factors, Tickeron's AI would currently favor XLV. The passive fund offers a 0.08% expense ratio versus 0.80% for MEDI, materially broader diversification, lower concentration risk, deeper liquidity, and a lower volatility profile. While MEDI presents a legitimate vehicle for investors seeking concentrated active exposure to high-growth biotechnology, its smaller scale, higher turnover, and single-name sensitivity introduce risks that weigh against it in a probabilistic assessment. For most investors building a core health care position, XLV appears to be the more robust, cost-efficient choice in the current environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations